Peptide fusion bio company NIBEC is set to actively pursue global joint development and commercialization of its sarcopenia treatment and next-generation drug delivery platform, PEPTARDEL.
On July 4, NIBEC announced that it held technology discussions with major global pharmaceutical companies at 'BIO USA 2025' in the United States last month, focusing on its core pipelines: the anti-aging peptide-based sarcopenia treatment and the next-generation drug delivery platform PEPTARDEL.
At BIO USA, NIBEC actively engaged in discussions on joint research and development with various global pharmaceutical companies, leveraging its anti-aging technology using stem cell-activating peptides and preclinical data. In the sarcopenia field, where no effective treatments currently exist, NIBEC's anti-aging program was recognized for its high level of innovation and potential for indication expansion, receiving positive feedback from potential partners.
The company also held follow-up meetings with a U.S. biotech firm with which it recently signed a technology transfer agreement, and explained that it is now entering a practical stage of collaboration. The technology transfer agreement is progressing smoothly into concrete implementation, and both companies are advancing commercialization strategies and development plans based on their collaborative structure as scheduled.
NIBEC also highlighted the technological strengths of its proprietary next-generation drug delivery platform, PEPTARDEL. PEPTARDEL is a targeted tissue-selective drug delivery system based on NIPEP-TPP, and is a next-generation drug delivery system (DDS) platform capable of being expanded into long-acting and oral formulations.
A NIBEC representative stated, "The anti-aging peptide is a highly expandable platform that can be applied not only to sarcopenia but also to a variety of age-related diseases," and added, "The follow-up procedures for the technology transfer agreement are also proceeding smoothly."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
